'Star Trek: Strange New Worlds' Season 3 Sets Premiere Date
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Entertainment gossip and news from Newsweek's network of contributors
It's been not quite two years since "Star Trek: Strange New Worlds" Season 2 ended on a huge cliffhanger, and now we finally know when to expect new episodes. As reported by The Hollywood Reporter, Season 3 of "Strange New Worlds" will debut with not one, but two new episodes on Paramount+ on Thursday, July 17.
Read More: Robert Picardo Teases Major Change to Character in 'Star Trek: Starfleet Academy'
After those first two episodes, new installments of "Strange New Worlds" will debut one episode at a time on Thursdays, with the season finale streaming on Thursday, September 11.
Anson Mount in "Star Trek: Strange New Worlds".
Anson Mount in "Star Trek: Strange New Worlds".
Paramount
Along with the news of the premiere date, Paramount+ also released a new poster for the season. You can see that below.
🚨BREAKING NEWS - SNW S3 PREMIERE DATE!
The long-awaited premiere date is here!#StrangeNewWorlds Season 3 sets course for its streaming premiere on July 17 on Paramount+ with a stunning new poster!#StarTrek pic.twitter.com/1nT3FtWSMw — Trek Central (@TheTrekCentral) May 15, 2025
Hopefully, the wait for a new season won't be quite as long next time. "Strange New Worlds" has been renewed for a fourth season ahead of the release of Season 3, and production on Season 4 is already underway.
Judging by a teaser released earlier this year, episodes of Season 3 include what appears to be a holodeck episode, one episode in which the ship gets hardwired with landlines, and at least one episode in which half the lead crew are surgically altered to appear as, and act, as Vulcans.
Season 2 of the sci-fi series ended with things looking particularly bad for our heroes. A chunk of the Enterprise crew had been captured by the reptilian Gorn, while the ship itself was under fire from more than a few Gorn ships. The Season 2 finale, "Hegemony", ends with Captain Pike (Anson Mount) speechless as to how to get out of his bind.
With the cancellation of both "Star Trek: Discovery" and "Star Trek: Lower Decks", "Star Trek: Strange New Worlds" is for now the only game in town as far as "Trek" is concerned. That is, it will be until the upcoming "Star Trek: Starfleet Academy" gets off the ground. The latter series has wrapped production but so far there's no official release window yet.
Then there's the live-action "Star Trek" workplace comedy that Tawny Newsome of "Star Trek: Lower Decks" fame is developing with Justin Simen.
"Star Trek: Strange New Worlds" stars Anson Mount, Rebecca Romijn, Ethan Peck, Jess Bush, Christina Chong, Celia Rose Gooding, Melissa Navia, Babs Olusanmokun and Martin Quinn. Guest stars for the upcoming season include Rhys Darby, Patton Oswalt, Cillian O'Sullivan, Melanie Scrofano, Carol Kane, and Paul Wesley.
More TV:
Recapping the Ending of 'Andor' Season 2: Everything You Need to Know
Every Actor Joining Tom Segura's Netflix Special, 'Bad Thoughts'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
an hour ago
- Forbes
This Billionaire Is Partnering With The Ellisons On The Paramount Deal
T he year-long saga of Skydance Media's $8 billion Paramount takeover is fit for its own Paramount+ mini-series. There's political intrigue with critics slamming departing boss Shari Redstone's apparent capitulation to Donald Trump to get the deal approved, including Paramount's agreement to pay $16 million to Trump's future presidential library to resolve a lawsuit over a 60 Minutes segment on Kamala Harris followed by CBS News' announcement that it was cancelling popular Trump critic Stephen Colbert's late-night show in 2026 (supposedly for financial reasons). Trump celebrated both announcements vociferously. Then there is the potential family intrigue worthy of a Succession spinoff: David Ellison, the Skydance founder and former Biden backer behind such films as 'Top Gun: Maverick' and 'True Grit', is teaming up with his staunch Republican father Larry Ellison who is the second richest person in the world and founder of software giant Oracle. Flying under the radar, beneath all the high-stakes drama, is Gerry Cardinale, a private equity investor who is poised to be an influential figure in the new-look Paramount. His firm RedBird Capital Partners is a shareholder in Skydance, having first invested in 2020. Now the firm is putting in $1.8 billion towards the $8 billion purchase price. Cardinale will join Paramount as a director and will appoint a yet-to-be-named second director. Jeff Shell, former CEO of NBCUniversal who chairs RedBird's sports and media business, will join Paramount as president. Andy Gordon, head of RedBird's West Coast office, will become Paramount's chief operating officer and chief strategic officer. Under the new ownership structure, RedBird will hold 22.5% of Paramount's voting rights, while David Ellison will hold 50% and Larry, who is Skydance's biggest investor, will hold the remaining 27.5%. This complicated familial-financial dynamic is likely to make Cardinale a pivotal voice in scenarios where the Ellisons butt heads. Paramount will become Cardinale's highest-profile investment but it's hardly his first big bet. In the worlds of sports, entertainment and media, the 57-year-old investor has been striking high-stakes deals for over a quarter of a century, first at Goldman Sachs and for the last decade at RedBird, which he founded in 2014. RedBird bought Italian football club A.C. Milan for $1.2 billion in 2022, and has backed household names like Lebron James, Dwayne 'The Rock' Johnson, and Ben Affleck and Matt Damon in their independent entertainment ventures. It has also hired big names like Jeff Zucker, former CNN president, who is now leading its acquisition of British broadsheet The Telegraph (alongside co-investor Abu Dhabi-based firm IMI) for $675 million. The firm has also invested a smaller portion of its funds capital ($1.5 billion) on financial services companies. Its willingness to dive into the nitty-gritty of portfolio companies and their operations has helped RedBird grow to $12 billion in assets under management with 100 investment professionals across six global offices. 'I like playing shadow entrepreneur and solving problems with capital,' Cardinal said on Bloomberg podcast The Deal last year. It's been a winning recipe so far: RedBird has delivered 2.5 times gross multiple of capital and a 33% internal rate of return, according to a person familiar with the matter. Cardinale owns 100% of RedBird, filings show, and Forbes estimates he is worth $1.8 billion. (He declined to comment on his net worth or be interviewed for this article). W all Street glory was not always in the cards for Cardinale, who once harbored dreams of being a diplomat. Born in 1967, he grew up in the leafy Main Line suburbs outside Philadelphia, the son of a trial attorney. He later studied social studies at Harvard, where he rowed heavyweight crew and graduated with honors before studying politics and political theory at Oxford as a Rhodes Scholar. Later on, he took a job at a Japanese think tank in Tokyo where he got a front-row seat to the effects of globalization. At the time, he was still considering law school, or getting his PhD in political theory. 'I wasn't one of these Wharton kids who knew I wanted to go to Wall Street from day one,' Cardinale recalled on The Deal. But meeting with investment bankers in Tokyo convinced Cardinale that finance would be a rewarding (and no doubt lucrative) career path. He joined Goldman Sachs as an analyst in 1992, the same year he published an article on Japanese anti-American sentiment and rising trade tensions in the academic journal Asian Survey . (His strong interest in Japan is something he shares with Larry Ellison, who has a Japanese art collection and modeled his Woodside, California home after a 16th century Japanese emperor's palace.) Cardinale worked at the bank's Hong Kong and Singapore offices before settling in the New York office in 1997 to work in the telecom, media and technology group as an investment banker. He later joined the bank's principal investment division, where he made his name persuading Yankees owner George Steinbrenner to launch the YES regional sports network in 2001. The project was finalized the day before September 11, and Goldman Sachs ended up backstopping the deal with a $335 million private equity investment after another investor pulled out. Though risky, the deal turned into a huge success, and Goldman made Cardinale a partner in 2004. A few years later in 2008, he persuaded Dallas Cowboys' billionaire owner Jerry Jones to team up with Steinbrenner to create the sports stadium concessions business Legends Hospitality, which investment firm Sixth Street Partners acquired a majority stake of in 2021. Cardinale left Goldman in 2013 and briefly worked at merchant bank BDT, founded by fellow Goldman alum Byron Trott, whom he'd previously done deals with. (BDT later merged with Michael Dell's family office to become BDT & MSD, and the firm has advised outgoing Paramount boss Shari Redstone). Cardinale founded RedBird in 2014 and raised $665 million for an inaugural fund from high-net-worth backers he'd met while at Goldman (their identities have not been disclosed) and an anchor investment from the Ontario Teachers' Pension Plan, which he also had a preexisting relationship with. RedBird became Skydance's second largest investor in 2020 when it led a $275 million capital raise. It backed Skydance again in 2022 when it raised another $400 million at a $4 billion valuation. RedBird's $1.8 billion cash outlay to buy Paramount represents 15% of its total assets under management. T he potential rewards from investing in Paramount are great but so are the risks: Between the inexorable decline of linear television, competition between streaming platforms, an existing $14.2 billion long-term debt load, and possible viewer blowback to perceived capitulation to Trump, Paramount faces a raft of challenges under its new ownership group. '[It] has the potential to overwhelm RedBird's portfolio,' Paul Wachter, the founder of Main Street Advisors, said earlier this year in a Harvard Business Review case study on RedBird. 'Turning Paramount around is going to be an enormous amount of work.' (Wachter also said he believes the investment will be a success 'because the executives are smart and highly motivated.') From Cardinale's perspective, the new Paramount—with its more than 1,200 film titles, distribution rights to another 2,400 films, and roster of television networks emblazoned in the American viewer psyche—is the perfect candidate to receive the RedBird treatment. 'What we do at RedBird is we look for ways of monetizing world-class IP. This is an over 100-year-old business…with really high-quality intellectual property,' he said last year on The Town, Puck founder Matthew Belloni's podcast, after the Skydance-Paramount deal was announced. 'We're not just deal guys looking to do a deal; we're not just private equity guys looking to go buy something.' While investors eye the numbers, media critics and consumers will be waiting to see how Skydance follows through on what the FCC described as its 'written commitments to ensure that the new company's programming embodies a diversity of viewpoints from across the political and ideological spectrum' and to 'adopt measures that can root out the bias that has undermined trust in the national news media.' There are reasons to believe the new Paramount will be less Trumpy than some fear: David Ellison gave around $1 million to Joe Biden's reelection campaign, and Cardinale, while not a megadonor, has previously given to both Democrats and Republicans. In any case, Cardinale has more to worry about than politics. With its massive debt load and facing structural headwinds, the new-look Paramount is crying out for a financier who understands the industry and is willing to stake his reputation on it. The test begins when the deal closes - which could happen any day now. More from Forbes Forbes How The World's Second-Richest Person And His Son Pulled Off The $8 Billion Paramount Deal By Phoebe Liu Forbes Inside Private Equity's $29 Trillion Retirement Savings Grab By Hank Tucker Forbes Want To Hedge Against Inflation? Buy A Forest By William Baldwin Forbes The New Owner Of The San Diego Wave Soccer Team Is The World's First Woman Private Equity Billionaire By Giacomo Tognini
Newsweek
2 hours ago
- Newsweek
Fox News Discusses Sydney Sweeney Marrying Barron Trump
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Fox News host Jesse Watters made a bold statement about Sydney Sweeney and Barron Trump. During Monday's episode of The Five, Watters playfully said the Euphoria star, 27, and President Donald Trump's son, 19, will "marry." Newsweek reached out to Sweeney and Barron Trump's representatives for comment on Tuesday via email outside regular working hours. Why It Matters Watters' statement comes as Newsweek and other outlets confirmed over the weekend that Sweeney is registered as a Republican in Monroe County, Florida. The White Lotus actress also made headlines recently for her American Eagle jeans ad. The commercial, which is titled "Sydney Sweeney Has Great Jeans," sparked a conversation about eugenics and racism online, with some branding it "Nazi propaganda." Jesse Watters as "Jesse Watters Primetime" debuts on Fox News on July 17, 2023 in New York City. In the inset image, Sydney Sweeney attends the 2024 People's Choice Awards on February 18, 2024 in... Jesse Watters as "Jesse Watters Primetime" debuts on Fox News on July 17, 2023 in New York City. In the inset image, Sydney Sweeney attends the 2024 People's Choice Awards on February 18, 2024 in Santa Monica, California. More;What To Know On The Five, a talk show on Fox News, Watters suggested Sweeney could potentially marry Barron Trump, the youngest son of President Donald Trump and the only child of first lady Melania Trump. "Every girl wants to look like her, and every guy wants to look at her," he said of Sweeney. "And the Democrats think, 'Wait a second, why don't we call her a Nazi and boycott the company?'" "You know how this ends? She's gonna marry Barron [Trump], and it's going to create the greatest political dynasty in American history," Watters added in a tongue-in-cheek manner, seemingly referring to Sweeney's recent association to right-leaning politics by conservatives. Watters: You know how this ends? Sydney Sweeney is going to marry Barron Trump and it's going to create the greatest political dynasty in American history. — Acyn (@Acyn) August 4, 2025 In the American Eagle ad, Sweeney, clad in a blue double-denim look, said, "Genes are passed down from parents to offspring, often determining traits like hair color, personality and even eye jeans are blue." Discourse about the campaign played out across TikTok, Instagram, Threads and X, with critics arguing that the play on "genes" echoes eugenics ideology, which promoted white genetic superiority and enabled the forced sterilization of marginalized groups. The backlash though, was dismissed by many, with some users viewing the play on words as creative marketing, and others celebrating the ad for what they described as a pushback against "woke." Barron Trump has largely stayed out of the spotlight despite his parents' public lives. He's currently a New York University student and does not have a known social media presence, according to The Palm Beach Post newspaper. What People Are Saying American Eagle responded to the widespread criticism in an Instagram post on Saturday: "'Sydney Sweeney Has Great Jeans' is and always was about the jeans. Her jeans. Her story. We'll continue to celebrate how everyone wears their AE jeans with confidence, their way. Great jeans look good on everyone." Donald Trump told reporters on Sunday: "She's a registered Republican? Oh, now I love her ad!" The president doubled down on his statement in a message posted to Truth Social on Monday: "Sydney Sweeney, a registered Republican, has the 'HOTTEST' ad out there. It's for American Eagle, and the jeans are 'flying off the shelves.' Go get 'em Sydney! On the other side of the ledger, Jaguar did a stupid, and seriously WOKE advertisement, THAT IS A TOTAL DISASTER! The CEO just resigned in disgrace, and the company is in absolute turmoil. Who wants to buy a Jaguar after looking at that disgraceful ad. Shouldn't they have learned a lesson from Bud Lite, which went Woke and essentially destroyed, in a short campaign, the Company. The market cap destruction has been unprecedented, with BILLIONS OF DOLLARS SO FOOLISHLY LOST. Or just look at Woke singer Taylor Swift. Ever since I alerted the world as to what she was by saying on TRUTH that I can't stand her (HATE!). She was booed out of the Super Bowl and became, NO LONGER HOT. The tide has seriously turned—Being WOKE is for losers, being Republican is what you want to be. Thank you for your attention to this matter!" White House Director of Communications Steven Cheung said on X: "Cancel culture run amok. This warped, moronic, and dense liberal thinking is a big reason why Americans voted the way they did in 2024. They're tired of this bulls***." Robin Landa, an advertising expert and professor at Michael Graves College at Kean University, previously told Newsweek: "The campaign's pun isn't just tone-deaf—it's historically loaded." Megyn Kelly, host of The Megyn Kelly Show, said on the show: "We're sick and f****** tired of the nonsense, where you are not allowed to ever celebrate someone who is white and blonde and blue-eyed. That we have to walk into a room apologetic for those things, or have for the past five years. In a way, this ad is the final declaration that we're done doing that s***. It doesn't mean we're better, but you know what? We're no worse than any other race or any other hair color or eye color." What Happens Next Sweeney's new film Americana hits theaters on August 15.
Newsweek
2 hours ago
- Newsweek
Emerging Treatment Could 'Significantly Improve' This Chronic Condition
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A new study by the University of Virginia and Virginia Commonwealth University has found that a drug typically used in the treatment of heart failure has notable positive effects for patients with a common chronic illness. The drug ivabradine has been on the market for years as a medication for heart failure, but more recently has been found to help patients with Postural Orthostatic Tachycardia Syndrome (PoTS). Ivabradine became available in the U.S. about 10 years ago having previously been available in the U.K. and other countries, Dr. Svetlana Blitshteyn, professor of neurology at the University at Buffalo, told Newsweek. Commenting on ivabradine's use, Professor Lesley Kavi, the chairperson of the U.K.-based charity organization PoTS UK, told Newsweek that U.K.-based PoTS specialists "have a lot of experience of prescribing it." "It's often their first choice treatment if self management strategies are not sufficient and our experience as a charity is that patients find it very helpful," she added. Some U.S. doctors have been prescribing the drug to PoTS patients for a number of years, with other studies noting its positive effect on patients—with one finding the drug had an 88 percent improvement rate on symptoms. Other studies have found a marked improvement in symptoms for children with the condition, particularly an improvement on sudden losses of consciousness, lightheadedness and fatigue. Therefore, while the drug is not new, nor newly prescribed to PoTS patients, the two Virginia universities' study—published in the Journal of Cardiovascular Pharmacology in July—adds to a body of research revealing the largely positive impact the drug can have on PoTS symptoms. A file photo shows a medical professional monitoring a patient's heart rate. A file photo shows a medical professional monitoring a patient's heart Is PoTS? PoTS is understood as an abnormality in the functioning of the autonomic nervous system, the system controlling breathing, gut function, heart rate, blood pressure and many other bodily functions. It results in a wide range of symptoms, particularly when standing, such as increased heart rate, chest pain, hot flushes, nausea, dizziness, feeling faint, headaches, tunnel or blurred vision and more. As symptoms tend to persist when standing, the condition can have huge impacts on patients' lives, because many basic tasks require postural changes and standing. Why this happens for patients with PoTS is still under investigation, but mechanisms, such as "low blood volume, abnormal blood flow, hyperadrenergic state, immunologic changes and small fiber neuropathy, may be among the reasons," Blitshteyn said. Some research has also suggested PoTS is an autoimmune condition, Dr. Blair Grubb, a professor of medicine, pediatrics and neurology and director of the Cardiac Electrophysiology Program at the University of Toledo Medical Center, told Newsweek, adding it could be triggered by a viral infection. PoTS is believed to affect millions of Americans—although exact estimates vary widely, which some experts believe is because it is under-recognized. In the wake of the COVID pandemic, the condition has become more recognized as the prevalence of PoTS has been dramatically increasing. "Post-COVID, nationwide, the incidence of PoTS went up fivefold," Grubb said. While awareness is increasing, there is still a long way to go. "It's very unfortunate because these people are mistreated and ignored, and I think the real reason is many of them are women," he said. "If this was a disease principally in men it would be taken more seriously." "There is a real tendency in America to blame the patient for their illness and women are just ignored," he said, adding women were often passed off as being "hysterical" by some health care professionals. Additionally, there are also not enough doctors treating the condition, Dr. Satish Raj, a professor of cardiac sciences, director of the Calgary Autonomic Investigation and Management Clinic, and director of education at the Libin Cardiovascular Institute, told Newsweek. "Most specialized autonomic clinics have waiting lists of one year or more," he said. "These patients require a lot of time to understand the issues and to iteratively try treatments," he added. "Health insurance does not pay well for talking to and assessing complex patients—they pay for procedures. This is not a procedure-intensive problem." What The Study Found In an analysis of 10 patients with PoTS, researchers found that ivabradine reduced their heart rate while "significantly improving" other symptoms. The study revealed that participants' heart rate was significantly decreased after taking the drug—a change from a 40 beats per minute (bpm) increase on standing, to a 15 bpm increase. Other symptoms were also eased by the drug, with patients reporting the greatest improvement in "feeling faint," which decreased by 69 percent after taking ivabradine, and "chest pain," which decreased by 66 percent. The researchers said that the overall improvement in symptoms, via a reduction in heart rate, suggests that "the heart rate issue is an underlying driver of other PoTS symptoms." The patients involved in the study had an average age of 28, with an age range of 21 to 36, and eight of the 10 participants were women. Three of the cases followed a viral illness, with two following a COVID infection. While other drugs can reduce heart rate, the notable difference about ivabradine is that it does not affect a person's blood pressure. For PoTS patients, changes to blood pressure can exacerbate symptoms. An "uncontrolled heart rate can contribute significantly to different symptoms in PoTS, so lowering heart rate definitely helps with overall symptoms control," Raj said. He said that the lightheadedness and "feeling faint" that PoTS patients typically experience can "often be due to high heart rates and decreased filling time in the heart that can decrease blood flow," so lowering the heart rate can help with that—as well as easing symptoms like nausea, and occasionally headaches. Kavi said that, while it is not fully understood, "it is likely that reducing heart rate a little improves the ability of the heart to pump and maintain blood pressure and blood supply to organs, thereby reducing other symptoms too." What The Study Means For PoTS Treatment PoTS patients are often prescribed beta-blockers for symptom management, and while these drugs can reduce heart rate and have a positive impact for some patients, they can also affect blood pressure. This means that in some PoTS patients, beta-blockers can enhance dizziness and lightheadedness, as well as causing a number of other unwanted side effects. Ivabradine could therefore be an effective alternative medication for PoTS patients who do not respond well to beta-blockers. "Drugs like beta blockers can lower blood pressure and can make people feel lousy," Grubb said. "Beta blockers can make people feel depressed and terrible, but ivabradine lowers heart rate with no effect on blood pressure, so it's kind of the ideal drug." Grubb said he has been using ivabradine in his clinic for PoTS patients for a number of years. "It's an extremely valuable drug that we use, and it's actually become a first-line drug in treating our patients," he said. However, given their positive effect for some patients, "beta blockers continue to be the first choice for treatment of PoTS and other forms of dysautonomia, in my experience," Blitshteyn said. "Obviously, the more medications we have available for the treatment of PoTS, the better it is for patients," she said. Blitshteyn added that ivabradine is also one of the medications being looked at in terms of post-COVID PoTS in the NIH-RECOVER Autonomic trials, a research program aimed at investigating, diagnosing and treating long COVID. An Underrecognized Condition While ivabradine has been around for some time, it has been approved for heart failure and not for PoTS, Raj said. "It can be difficult for patients with PoTS to be able to get the medication approved by their insurance companies," he said, adding access is therefore "more limited than it should be." Additionally, "education of medical students and doctors on autonomic disorders, including PoTS, is still lacking," Blitshteyn said. As a result, PoTS can often be "misdiagnosed with anxiety, depression, panic disorder, anemia, dehydration and many others, so when a doctor doesn't know much about PoTS, they are most likely to misdiagnose it," Blitshteyn added. "Psychological labeling is common especially in women and PoTS is much more common in women," Kavi said. Doctors usually have limited time to spend with patients, Blitshteyn added, but patients with PoTS are "often complex, requiring time, effort, knowledge and understanding." Kavi said that, since the COVID pandemic, "there has been an increase in awareness of PoTS by healthcare professionals, so more people are being diagnosed, although they often still have tortuous journeys to obtain a diagnosis." "There is consequently more demand for specialist services but no significant increase in capacity," Kavi added.
